An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients with Type 2 Diabetes Mellitus.
Phase of Trial: Phase III
Latest Information Update: 18 Jul 2014
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational
- Sponsors AstraZeneca
- 11 Jun 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01876849).
- 27 Jul 2011 New trial record